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ABSTRACT
Methamphetamine (METH) abuse is a persistent problem in the U.S. and abroad.
Escalation of METH use among independent users occurs for a variety of physiological and
psychological reasons. Methamphetamine dependence may be attributed to the rewarding
effect of this drug via the dopaminergic systems of the central nervous system (CNS). The
presence of METH in the CNS increases synaptic release of dopamine. This increase in
dopaminergic neurotransmission is thought to be directly attributed to the rewarding effects of
METH. Following METH use, compensatory changes have been found to occur in the
dopaminergic system during various periods of abstinence. It is proposed that these molecular
compensatory responses during periods of abstinence following stimulant usage may in part be
responsible for facilitating addiction behavior and drug relapse.
Previous studies have shown that rats given extended access to methamphetamine
self-administration display an escalation of drug intake as compared to animals given limited
access to this drug. Many other studies using both self-administration operant conditioning and
non-contingent delivery of METH in rodents have found various changes in key dopaminergic
proteins following access to high-dose METH under limited durations. However, dopaminergic
protein changes which may occur shortly following an extended access (20 days or more)
METH paradigm are not well-characterized. The goal of this study was to compare changes in
dopaminergic systems in rats allowed extended versus limited access to methamphetamine
self-administration following an extended access paradigm.
Adult Wistar rats (n=10 extended, n=7 limited, n=8 naïve) were given either extended (6
hr/day) or limited (1 hr/day) access to intravenous self-administration (IVSA) of METH (0.025
mg/infusion) for 28 days. Control rats received surgical implantation of intravenous catheters,
but were not given access to METH IVSA. The rats were sacrificed 72 hours after the final self-
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administration session. All groups were compared with respect to striatal dopaminergic protein
expression (Tyrosine hydroxylase, TH, dopamine transporter, DAT, and dopamine receptor 2,
D2R) using western-blot and immunocytochemistry procedures.
The results revealed that rats given extended access to METH displayed an escalation
of METH intake during the first hour of each session, and this behavior was not observed in
animals given limited access. Seventy-two hours after termination of extended access paradigm
the largest changes in striatal dopaminergic markers were observed between drug naïve
controls versus rats that self-administered METH for the extended access (6hrs) duration.
Western-blot analyses of striatal tissue revealed no significant difference in immunoreactivity for
TH between treatment groups and naïve animals. By contrast, a significant increase in total
striatal DAT was found in extended access self-administration rats as compared to naive
controls. Preliminary immunocytochemistry analysis was consistent with the latter results,
suggesting an increase in the levels of DAT throughout the corpus striatum. On the other hand,
no significant changes were found between METH IVSA and naïve controls for D2R striatal
immunoreactivity.
Taken together, our results revealed that rats allotted 6 hours access to METH IVSA
showed an escalation of intake compared to rats allotted 1 hour of access. In addition, it was
found that expression of dopaminergic markers in the striatum were altered after extended
methamphetamine self-administration access. These findings cast new insight into the
molecular mechanism of long-term METH use and subsequent escalation, which may evoke
cravings for sustained use and relapse during initial periods of withdrawal.
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CHAPTER 1: INTRODUCTION
1.1 Stimulants of Abuse
Among clinicians and researchers, drug addiction is widely considered a neurological
disorder characterized by a progression of drug intake and the meaningfulness of drug-related
stimuli manifesting into drug-seeking behavior (Everitt et al., 2008). Drug acquisition develops
into heavy consumption via a progressive transition from recreationally-mediated substance use
to disruptive substance abuse that can become obsessive and maladaptive. Drugs of abuse fall
into various broad categories of effect including stimulants and depressants. Among the
psychostimulants, the strong addictive properties of amphetamine and amphetamine-type
stimulant drugs render this structurally-related group particularly insidious. Commonly abused
substances classified under amphetamine-type stimulants include amphetamine (AMPH),
methamphetamine

(METH),

methcathinone,

3,

4-methylenedioxy-N-methylamphetamine

(MDMA) and MDMA synthetic analogues (Fleckenstein et al., 2007).
Among the commonly abused amphetamine-type stimulants, METH has become an
important public health issue both in the United States (U.S.) and abroad over the last 15 years.
Given the relative accessibility of precursor ingredients and easily-obtained instructions for
synthesis, the spread of METH production and use has become a major public health problem.
The number of reported METH-related laboratory seizures in the U.S. has increased by 26%
over the course of one year (UNODC, 2011). Additionally, METH trafficking along the U.S.
southern border and the number of first time users have been increasing annually since the mid
1990’s (El Paso DEA 2006 Intel Report and Gonzales et al., 2010). A report provided for the
2010 National Survey on Drug Use and Health estimated that 1.3 million people over the age of
12 have abused METH within their lifetime and nearly half of those reporting cited METH as
their drug of choice (NIH. NIDA. Drug abuse.gov).
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In the U.S., METH is federally regulated as a schedule 2 stimulant and is available by
prescription under the trade name Desoxyn®. The Desoxyn® is approved by the Food and Drug
Administration for the treatment of attention deficit/hyperactivity disorder (ADD/ADHD),
narcolepsy and severe cases of obesity. Systematic administration of METH at low
concentrations is fairly safe and therapeutic appetite suppressant. However, METH has been
shown to have a high potential for abuse and is noxious when administered in frequent high
doses. Recommended clinical dosing regimens prescribed initial dosages of 0.3-0.6mg/kg every
4-6hours with a gradual increase in dose over the course of a month until the desired effect is
achieved. For some users of the prescribed medication, the slowly escalating dosing regimen
proves therapeutic. However, this regimen has led to physical dependence and abuse among
some users attempting to achieve their desired effect. Due to the significant rewarding effects of
these molecules, METH has a great potential for abuse and potent adverse neurological effects
among users.
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1.2 Molecular Characterization
METH is a pyschostimulant of the central nervous system (CNS) and is part of the
phenethylamine and AMPH class of stimulant drugs. METH shares structural similarities with
endogenous neurotransmitters dopamine (DA) and norepinephrine (NE) (Table 1). The
phenethylamine structure (highlighted in blue, Table 1) is a naturally produced monoamine
alkaloid which serves as the central homology among these functionally related compounds.
Furthermore, it is the structural similarity that enables METH and other phenethylamine derived
compounds to produce reward-related effects through dopaminergic, serotonergic and
noradrenergic circuit hyper-activation (Fleckenstein et al., 2007). METH and its active
metabolite AMPH differ only in an additional methyl group bound to the amine group of METH.
The additional methyl configuration on METH potentiates the molecule’s efficacy by increasing
its lipophilicity and resistance to enzymatic degradation. This change results in a more rapid and
sustained subjective “high” compared to equivalent AMPH concentrations (Gulaboski et al.
2007).
Table 1. Structural similarity between drugs of abuse and endogenous neurotransmitters

All molecules share the phenethylamine structure highlighted in blue, (MDMA) - 3, 4methylenedioxy-N-methylamphetamine.
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The plasma membrane dopamine (DAT) and norepinephrine transporters (NET), and
the vesicular monoamine transporter (VMAT) are among three of METH’s principle targets. DAT
and NET, found at dopaminergic and noradrenergic pre-synaptic neurons, are responsible for
the uptake and clearance of their respective catecholamines, thus facilitating termination of
post-synaptic signaling. METH directly increases DA and NE release and synaptic availability
through several mechanisms (Eyerman & Yamamoto, 2007; Krasnova & Cadet, 2009). DAT is a
substrate for METH, inhibiting transporter function through competition with DA for re-uptake
(Fleckenstein et al. 1997). In addition, METH reverses DA transport from the cellular cytosol to
the extracellular space resulting in accumulation of extracellular DA (Kokoshka et al., 1998;
Goodwin et al., 2009; and Eyerman & Yamamoto., 2007). However, the specific molecular
process behind the reverse transport of DA induced by METH remains unclear.
In the pre-frontal cortex where DAT is represented in lower amounts compared to the
striatum, NET can transport both DA and NE, thus it is little surprise that METH is demonstrated
to interfere with NET function in a similar fashion to DAT, through both inhibition and reversal of
transport (Sofuoglu and Sewell 2009). NET inhibition increases the concentration of both
extracellular DA and NE, suggesting a functional coupling between the DA and NE systems in
the presence of METH-related stimulants (Wee and Woolverton., 2004). METH also increases
intracellular DA concentrations through interaction with the vesicular monoamine transporter 2
(VMAT2), which packages DA, NE and other catecholamines in synaptic vesicles of presynaptic
neurons for synaptic release (Fumagalli et al., 1999). As with DAT and NET, VMAT2 is also a
METH substrate (Wilhelm et al., 2006). In this system, METH enhances monoamine content
within the cytosol through reverse transport of the VMAT-2 (Wilhelm et al., 2006, Fumagalli et
al., 1999 and Vergo et al., 2007). In each case, transport function is reversed upon METH
presence, and the net enhancement of free cytosolic monoamines results in a cascading
mechanism involving DA depletion in dopaminergic neurons.
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The increase of free cytosolic and extracellular monoamines is theorized to contribute to
the neurotoxic effects associated with METH abuse. METH at high concentrations also may
lead to excessive dopaminergic oxidation via enzymatic degradation by monoamine oxidase
and self-oxidation, further compounding neurotoxicity (Wu et al., 2007). The cytotoxic effects of
METH can be indirectly assessed through measurement of tyrosine hydroxylase (TH), DAT, DA
receptors D1, D2 and neuronal cytoskeletal markers such as synaptophysin or MAP2 levels in
post-mortem brain sections or tissue extractions. Post-synaptically, METH decreases levels of
the DA receptors D2 and D1 (Barr et al., 2006). Co-administration of METH and DAT inhibitors
such as methylphenidate and amfonelic acid at high doses reduces METH-induced cell damage
(Marek et al., 1990; Schmidt and Gibb., 1985), lending strong support of METH’s reversal of
DAT and other monoamine transporters as a major factor in facilitating cell toxicity.
1.3 The Reward Pathway
The neural mechanisms underlying the transition to addiction are not completely
defined. However, results from numerous studies suggest primary involvement of the
mesocortiocolimbic DA system underlying addiction behavior (Self, 2004; Berke and Hyman,
2000; Everitt et al., 2008). Commonly referred to as the reward pathway (Figure 1.1), the
plethora of processes and behaviors influenced by the mesocorticolimbic and nigrostriatal
systems are vast in number and remain incompletely defined despite extensive characterization.
Within the systems, endogenous DA levels play a major modulatory role for many cognitive
functions in both vertebrates and invertebrates. DA influences arousal, attention, motivation,
locomotion, reward, learning and memory. The principle neurotransmitter involved in mediating
addiction behavior is DA (Berke and Hyman, 2000). Drugs of abuse produce a succession of
cellular signaling effects in the mesocorticolimbic system that result in tolerance, physical
dependency and behavioral sensitization (Self, 2004). Indeed, METH exposure can lead to
persistent deregulation of DA and DA modulating proteins within the system (McFadden et al.,
2012).
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The Mesocorticolimbic and Nigrostriatal Pathways (Reward Pathway)

Figure 1.1 - Sagittal illustration of the rat brain. The dopaminergic mesocorticolimbic
(orange) and nigrostriatal (red) pathways are highlighted. The nigrostriatal pathway extends
from the nuclei of the substantia nigra (SN, red) and terminates projections into the caudate
putamen (CPu, green). The mesocorticolimbic pathways extends from the nuclei of the ventral
tagmental area (VTA, red) and terminates projections into the caudate putamen (CPu, green),
nucleus accumbens (NAc, teal) and prefrontal cortex (PFC, blue). Collectively both pathways
are commonly referred to as the reward pathway.
Deregulation of the DA system has been associated with a number of neurological and
psychiatric disorders including Parkinson’s disease, depression, schizophrenia, attention deficit
disorder, and drug addiction. Many psychoactive substances of abuse stimulate the neural
reward circuitry of the mesolimbic system by increasing DA availability. METH acts on the
enhancement of dopaminergic neurotransmission within the mesolimbic circuit during drug
consumption. Enhancement in dopaminergic transmission is implicated in conveying a
behavioral reward response in the form of self-administration with various substances of abuse
(Berke and Hyman, 2000). Abnormalities in the regulation of the mesocortical pathway have
also been implicated in drug-induced psychosis (Contreras et al., 2002).
Withdrawal evoked by the absence of an abused stimulant is associated with depletion
of DA activity in the mesolimbic pathway (for a review see Dackis and Gold, 1985). Selfadministration of METH produces a transient DA depletion with a more persistent increase in
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DA turnover after 48 hours of abstinence (Brennan et al., 2009). In addition, the length of the
abstinence period is correlated with the time required for DA to return to pre-abstinence values
(Ciano et al., 2002). The pathway has also been shown to become activated via stimulation by
not only drugs of abuse but also drug-related stimuli and stress during periods of abstinence
(Self, 2004; Everitt et al., 2008). Taken together, these studies support the role of the
mesolimbic DA system in mediating drug addiction.
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1.4 Addiction Behavior and Neuronal Plasticity
Within the mesolimbic/mesocortical pathways, increases in available DA result in the
rewarding sensations associated with drug intake. The changes that induce compulsive
behaviors characteristic of addiction are mediated by the dorsal striatum, which is composed of
the caudate nucleus and putamen. Increases of DA in the nucleus accumbens (NAc) and the
caudate putamen (CPu) are associated with further motivating drug-seeking behaviors including
NAc reinforcement (Keller et al., 2007; Krasnova et al., 2010 and Cadet et al., 2009). The
alterations leading to habitual and compulsive behaviors involve the dorsal striatum (Everitt
2008).
Belin and Everitt (2008) demonstrated that bilateral infusions of a DA antagonist into the
dorsal striatum of rats suppressed response to a stimulus associated with cocaine, while a
unilateral lesion of the NAc had no effect. However, a unilateral lesion of the NAc coupled with a
dopamine antagonist infusion into the contralateral dorsal striatum suppressed responding for a
cue light associated with drug delivery (Belin and Everitt 2008). Thus, addiction-mediated brain
changes appear to follow a cascading set of connections from the ventral and dorsal striatum.
These studies provide a rationale for the present work, which focuses on neuronal adaptations
within the DA system of the striatum.
METH users suffering from physical dependence often report noxious symptoms during
early periods of abstinence which likely contribute to relapse. In a notable clinical case study,
depression, agitation, anxiety and craving for METH were all reported to be highest between 24
to 72 hours following the last METH dose among chronic METH users (McGregor et al., 2004).
Other atypical behaviors exhibited by METH users include profound increases in motor activity
and a progressive transition to compulsive drug-self-administration.
Animal studies have modeled this transition to dramatic escalation in drug consumption
during intravenous self-administration (Ahmed&Koob, 1998; Ahmed et al., 2000; and Koob et
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al., 2006). Intravenous self-administration (IVSA) is an experimental methodology wherein an
animal is trained to press a lever in an operant conditioning chamber, resulting in the delivery of
a reward drug at a specified volume and concentration through a syringe pump into a connected
external jugular catheter implant (Ahmed&Koob, 1998; Ahmed et al., 2000; Cadet et al., 2009;
McFadden et al., 2012; Volz et al., 2007; Schwendt et al., 2009; Krasnova et al., 2010; and
Koob et al., 2006). Various adaptations of the IVSA methodology are informed by clinical
findings to best mimic human drug consumption.
Prolonged METH IVSA can result in a maladaptation of neuronal protein expression and
function characterized by substance-dependent behaviors which include physical dependency.
Indeed, METH IVSA studies have revealed significant changes in various striatal dopaminergic
proteins within areas of the CPu, NAc, ventral tegmental area (VTA) and substantia nigra
following prolonged METH abstinence. Large quantities of self-administered METH have shown
a persistent down-regulation of DAT, TH, D2/D1 and DA content in various regions of the
mesolimbic pathway several days following the last rodent self-administration, suggesting that
endogenous DA signaling in the absence of METH is greatly diminished (Volz et al., 2007;
Schwendt et al., 2009; Krasnova et al., 2010; Cadet et al., 2009 and McFadden et al., 2012).
This establishes a DA depletion mechanism perhaps facilitating both physiological dependence
and escalation.
It is hypothesized that DAT and other key dopaminergic modulatory proteins play a
pivotal role in not only generating reward but also in mediating relapse of drug seeking
behaviors. However, it remains unclear whether these changes in striatal protein expression are
a part of a plastic compensatory response to the drug or a result from METH induced neuronal
toxicity. In addition, changes in striatal dopaminergic markers following METH IVSA at
concentrations below 0.06 mg/infusion during extended IVSA remains to be further
characterized.
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1.5 Objectives
Studies examining the effects of METH exposure have focused on changes within the
mesocorticolimbic system. A majority of the research examining the neurochemical effects of
METH have used animal models involving non-contingent administration of bolus injections of
neurotoxic doses of METH (i.e., experimenter-administered). The METH IVSA paradigm used in
the current study attempts to be more consistent with self-administered METH in humans.
Studies that compared the neurological effects resulting from contingent (self-administered) or
non-contingent exposure to METH have shown significant differences. For example, contingent,
but not non-contingent, exposure to METH resulted in a loss of D2R protein expression within
the VTA accompanied by an attenuation of D1R protein expression in the NAc after a 24-hour
period of abstinence (Stefanski et al., 1999).
Several regulatory proteins of the reward pathway have been investigated during periods
of METH abstinence several days and weeks following METH IVSA exposure. METH IVSA
studies have focused on changes in regulatory dopaminergic proteins in response to high selfadministered METH concentrations. One such study found a decrease in striatal DAT transport
function and expression following both 8-day and 1-month of abstinence periods from METH
IVSA (McFadden et al., 2011). Another study revealed significant decreases in both DAT and
TH protein expression in the NAc 14 days following METH exposure while expression was
significantly increased in the VTA 48 hours following a non-contingent METH escalation
paradigm (Keller et al., 2011). The majority of the rodent METH IVSA studies have found
decreases in striatal dopaminergic proteins following prolonged abstinence in higher dose
METH (0.06 mg/infusion fixed for 500 g; 0.1+ mg/kg/infusion) treated animals when compared
to naïve controls. While the effects of larger self-administered METH doses following prolonged
periods of abstinence have been fairly well characterized in the literature, little is known about
the effects of 0.025mg/infusion METH fixed for 500 g 72 hrs following an extended access selfadministration paradigm.
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Clinical studies have shown that METH users have difficulty maintaining abstinence for
periods longer than a week because of the emergence of compulsive drug craving (McGregor et
al., 2004). Other reports have also revealed a high intensity of withdrawal symptoms during
immediate withdrawal from METH (Newton et al., 2004; McGregor et al., 2004). Despite strong
clinical evidence that early time points of withdrawal are critical, changes in dopaminergic
systems within the striatum during the first 72 hours of METH abstinence have not been well
characterized. To get more insight into this mechanism, the main objective of this study is to
provide a detailed evaluation of changes in DA systems within the striatum during acute
withdrawal following extended access to METH self-administration. This study was carried
out using adult male Wistar Rattus and focused on three proteins involved in regulating
dopaminergic signaling including the D2 receptor, DAT and TH. The knowledge gained from this
study will clarify how certain key modulators of dopaminergic neurotransmission are affected
following extended access self-administration to low concentrations of METH in rats and other
mammalian model systems.
Specifically, this study examined changes in the DAT, TH and D2R protein expression
within the rodent striatum after a 72 hour period of METH abstinence following extended METH
IVSA access. Our study uses an IVSA paradigm adapted from Koob et al., (2006) in which rats
receive either extended, limited, or no access to METH IVSA (naïve). This extended access
IVSA paradigm is used to investigate the progressive transition from a controlled form of
administration to an arguably uncontrolled form of METH intake characterized by a significant
escalation in drug consumption. We hypothesize that rats given extended access will
escalate METH intake relative to short access, and dopaminergic protein expression will
decrease in all METH treated animals when compared to naïve controls.
.
.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Subjects
Male Wistar rats were purchased from Harlan, Inc. (300-350g) and housed two per cage
in a temperature-controlled vivarium under a reversed light/dark cycle (lights off 8:30am8:30pm). Each rat was handled for 5 days prior to food training and individually housed following
catheter implant surgery.

All procedures were performed during the animal’s dark phase.

Twenty-six animals completed the studies. Food and water were freely available in their home
cage except for one hour prior to operant food training and during all methamphetamine selfadministration sessions. All surgical and experimental procedures were carried out in strict
adherence to the National Institutes of Health Guide for the Care and Use of Laboratory Animals
(NIH publication number 85–23, revised 1996) and approved by the Institutional Animal Care
and Use Committee of the University of Texas at El Paso.
2.2 Apparatus
An operant conditioning chamber with dual retractable levers, in house cue-light and
food deposit well was used. A swivel above the chambers allowed free movement of
catheterized animals in the operant chamber. The in-house cue-light was positioned in the top
right corner on the opposite side of the wall from the active levers. An infusion pump was
positioned on the top of each chamber and connected through a silastic tygon tube shielded by
a steel tether. The silastic tube is inserted and secured by the steel tether to the animal’s
catheter outlet. The chamber functions for lever activity and cue durations were controlled with
custom software designed for animal operant conditioning.
Food training and self-administration occurred within the same operant conditioning
chambers with active lever settings consistent between both phases. The stimulus light turned
on for 20 seconds, coinciding with the onset of the injection, during which the lever became
inactive for a 20 second period. During the food training session food pellets (45mg) were
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delivered upon active lever presses from an automatic food dispenser fixed to the outside wall
of the chamber. A single lever press during food training resulted in the delivery of a food pellet
into the chamber dispenser well. Lever pressing for methamphetamine self-administration was
reinforced on a continuous reinforcement schedule (fixed ratio 1; (FR1)). A single lever press
resulted in a 2 second intravenous infusion (0.1 ml) of methamphetamine at a dose of 0.025
mg/infusion.
2.3 Catheter & Surgical Procedure
Catheters were constructed in the laboratory using a 14 cm piece of silastic tubing (0.30
mm inner diameter, 0.64 mm outer diameter) fitted to a 26-gauge stainless steel cannula and
fixed in a dental acrylic mold with a supportive nylon mesh attached to the base of the catheter.
A dremmel sander was used to smooth the cannula outlet and HEMO-D was used to aid in tube
fitting. Tubing was allowed to dry overnight and aquarium sealant was used to create a small
ball for the purpose of securing the inserted tube in place above the vein. Assembly was carried
out on a metal molding scaffold with dental acrylic placed on a cut mesh template.
Prior to implantation, all constructed catheters were tested to ensure there were no leaks
in the tubing prior to implantation. Rats were anesthetized using 2-3.5% isoflurane in mixture
with oxygen, and an indwelling jugular vein catheter implanted as described by Koob et al.,
(2006). Briefly, the outlet of the catheter was implanted subcutaneously in the upper back
between the shoulders and the free end of the tubing was inserted into the right jugular vein.
Silk size 5 sutures were used to secure the tubing to the vein. Isolation of the right jugular vein
for tube insertion required a small 1 cm incision on the upper chest. The free end of the tubing
was run through the epidermis tissue from the back incision to the upper chest incision using a
tissue boring tool. Silk size 3 sutures were used to close the chest incision and sterile surgical
staples used to close the back mount incision.
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Each rat received 2.5 mg/kg flunixin megluine (s.c.) and 1% Thermazine antibiotic
ointment on the day of the surgery and daily four days after during post-op recovery.
Immediately following surgery and for the remainder of the study each rat was infused with
approximately 0.2 ml of sterile saline solution containing heparin (1000 USP units/ml) and
Timentin (ticarcillin disodium and clavulanate potassium in 3.0 g/100 mg proportion, 100 mg/ml)
through the catheter back mount. Each rat was individually housed with surgical bedding and
access to food and water. Catheter patency was verified by infusing 0.05-0.1ml (10 mg/ml)
methohexital, which produces rapid and reversible anesthesia.
2.4 Food Self-Administration
Naïve rats, approximately 46 days old were first trained to associate lever pressing with
delivery of a reward. Each lever press during food training resulted in the delivery of a food
reinforcement (45 mg pellet) on a fixed ratio 1 schedule. Subjects were food restricted daily for 2
hours prior to food training (FT) sessions, except during the last 2 sessions which were
conducted under parameters synonymous to those used in the METH IVSA phase of the study.
All parameters were held constant throughout the training with the exception of the time out
duration and stimulus light which eventually reached 20 second following activation of food
reward.
At the start of food training, the duration of the time out and stimulus light (5 seconds)
were lowered in order to facilitate prompt acquisition of the operant behavior. Once the majority
of subjects had acquired the association between reward and lever press, the durations of both
the time out and stimulus light were gradually increased to 20 second periods. Operant behavior
was typically acquired within 4-5 days of food training and never exceeded a week in duration.
All subjects were allotted a 1-2 day break prior to catheterization procedures.
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2.5 Drugs
Methamphetamine hydrochloride (99%; M-8750, Sigma-Aldrich, St. Louis, MO) was
dissolved in sterile saline (0.9% NaCl), with the dose described as the free base form. The
METH solution was a concentration of 0.25 mg/ml which was administered at 0.025 mg/infusion
fixed for 500 g. Flunixin meglumine (2.5 mg/kg; Schering-Plough Animal Health Corp., Union,
NJ) was administered sub-cutaneously for post-surgery analgesia. Isoflurane 2-3.5% vapor
(99.9%, VEDCO, Inc. St. Joseph, MO) was used to anesthetize all animals. The antibiotic
Timentin (100 mg/ml; Glaxo-SmithKline) was dissolved in heparinized saline (1,000 USP
unit/mL; APP Pharmaceuticals) and administered (0.02-0.04 ml) after catheter implantation,
throughout post-surgical recovery and before and after every methamphetamine selfadministration session. Thermazine anti-biotic cream ointment (1% Silver Sulfadialzine; Kendall
Company, Mansfield, MA) was applied on all surgical incisions daily through post-op surgical
care.
2.6 METH self-administration
A modification of Koob et al. (2006) extended access escalation paradigm was used for
self-administration of METH. Following completion of surgical recovery all experimental rats
underwent one hour METH self-administration sessions for 6 days at fixed ratio of 1 with a 2
second pump infusion and a 20 second lever TO during their dark cycle at 0.025 mg/infusion at
a fixed rate of 500g. Individual rat weight was recorded every day and total daily mg/kg was
calculated based upon updated weight recordings. At the end of the initial drug acquisition
phase, total active lever presses for each rat were recorded in order to balance and divide two
separate groups based upon equivocal group presses and METH intake averages. Once the
rats were evenly separated, they underwent 22 days of METH self-administration (for 1
hr/session; or for 6 hr/session). The session schedule allowed for the rats to self-administer
methamphetamine for 6 days out of the week. All active lever presses were recorded for each
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animal daily and calculated with body weight to obtain the animal’s mg/kg of self-administrated
methamphetamine. At the final session the total mg/kg methamphetamine consumption was
calculated based upon daily recordings.
2.7 Perfusion and tissue preparation
Rats allocated for immunohistochemical analyses were transcardially perfused 72 hrs
after the final METH self-administration session. Rats were weighed and deeply anesthetized by
an intraperitoneal injection (i.p.) of 100 mg/kg sodium pentobarbital (Nembutal®; McKesson,
Washington Courthouse, OH). Perfusion through the ascending aorta was done using ~ 100 mL
of ice-cold 0.9% saline, followed by 400–500 mL of ice-cold 4% paraformaldehyde (JTBaker,
Inc., Pittsburg, NJ) at pH 9.5 with 0.1 M sodium tetraborate (Sigma-Aldrich, St. Louis, MO).
Brain tissues were then extracted and post-fixed for 5 hrs at 4 °C in the same solution, followed
by cryoprotection overnight at 4 °C in KPBS (0.02 M potassium phosphate, 150 mM NaCl)
containing 10% sucrose.
At the time of sectioning, brains were removed from cryoprotectant, mounted on a
tabletop freezing microtome (Model SM 2000R; Leica Microsystems, Bannockburn, IL), and
serial frozen sections taken in the coronal plane from a block of brain tissue containing the
caudate putamen. Five 1:5 series at 30 μm intervals were collected into antifreeze (30%
ethylene glycol, 20% glycerol) and stored at − 20 °C until used for immunohistochemical
analyses.
Rats allocated for western blot analyses were sacrificed 72 hrs after the final selfadministration session by conscious rapid decapitation. Following rapid decapitation, the
striatum from both hemispheres of each rat brain was extracted and placed immediately on top
of filter paper placed over a glass petri dish lid in ice. Extraction of the striatum was performed
using an autoclaved stainless steel spatula, and immediately, the tissue from both hemispheres
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was homogenized in 10mls of ice cold lysis buffer (200 mM Hepes, 100 mM NaCl, 15 mM
Imidozole, 10% Glycerol, 1% Triton, 10mg/ml, pH 8.0, 1% Sodium Deoxycholate) with protease
inhibitors (1 mM PMSF, 1.53 mM Aprotin, 2.10 mM Leupeptin, 0.5 M EDTA, 1 M NaF, 10 mM
NEM, 10% SDS, 5.7 M DFP).
Tissue lysis was completed using an electronic homogenizer, in ice, at its lowest speed
setting to prevent heating and denaturation of the sample. All samples were homogenized in
15ml falcon tubes while in ice. All lysed samples were centrifuged at 13,000 rpm g for 20
minutes at 4 °C and the supernatants were collected into individual 1ml aliquots in sterile 1.5ml
eppendorf tubes and stored at -80 °C until protein analysis was carried out. Lysates were
allowed to thaw in ice from storage and protein totals from each sample were quantified in µg
using the Lowry protein assay as described by Lowry et al. (1951).
Table 2. Chronological METH IVSA Outline
U

U

Table outlining the animal operant conditioning experimental design applied in this study.

2.8 Western blotting
Western blotting was conducted according to Current Protocols in Molecular Biology
(10.2A.1-13.Vol 2. 1999). Equal amounts of protein (30 µg) were loaded into each well of a
prepared 8% SDS-Page Bis-Acrylamide (37.5:1) gradient gel (Fisher BioReagents, Fair Lawn,
NJ) and electrophoresed by using a Thermo Electron EC105 (Thermo Fisher Scientific,
Waltham, MA). The proteins were allowed to separate overnight 18-20 hrs at 35 volts constant.
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Transfer of proteins occurred at duration 1.5h at 95 volts constant using a Bio Rad Powerpac
HC onto nitrocellulose membrane (Bio-Rad Laboratories) in transfer buffer solution (25 mM
Trizma Base, 192 mM Glycine, 10% Methanol). Membranes were blocked overnight (18 hrs)
with a 5% milk solution and washed five times in Tris-buffed saline with Tween 20 (20 mM Tris,
150 mM NaCl, .1% Tween, pH 7.5).
Incubation of all primary anti-bodies used in western blot analyses (table. 3) occurred at
4 °C overnight 18-20 hrs using 1:1000 dilutions for DAT (SC-1433, Santa Cruz Biotechnologies,
Santa Cruz, CA), TH (MAB318; Millipore Corporation, Billerica, MA), D2 (AB5084P; Millipore
Corporation, Billerica, MA) or Actin (A 2066, Sigma-Aldrich, St. Louis, MO) on a DS-500E VWR
Orbital Shaker (VWR International, Radnor, PA). All nitrocellulose membranes were then
washed five times for 5 min each wash with Tris-buffered saline with Tween (TBST) and
incubated for 1 hr with a horseradish peroxidase-conjugated secondary antibody (Promega,
Madison, WI). After five washes at 5 min per wash in TBST, the bands were visualized by using
SuperSignal® West Pico Chemiluminescent Substrate (34080; Thermo Scientific, Rockford, IL).
The resulting protein immunoreactivity was captured using premium x-ray film (Phenix Research
Products, Candler, MC) and quantified by densitometry with Adobe Photoshop’s histogram
measurement analysis. Immunoreactivity was normalized from arbitrary units to percentage of
naïve control.
2.9 Immunohistochemistry
Coronal sections (30 μm) were washed with Tris-buffered saline (TBS) (pH 7.4; 2-3
washes; 10 min each), and permeabilized with TBS containing 0.3% Triton X-100 (Triton) for
45–50 min. Sections were incubated in blocking solution (0.1% Triton, 2% normal goat serum
diluted in TBS) for 1 hr at 25 °C. Sections were then incubated with the primary antibody diluted
in blocking solution for 18-20 hrs at 4 °C followed by five 10 min washes with TBST (TBS-0.1%
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Triton). After washes, sections were incubated with secondary antibody for 4 hrs at 25 °C
followed by five 10 min washes with TBST. The primary antibody solution contained a mixture of
both primary antibodies, DAT and TH (Table 3), diluted in blocking solution. Primary (DAT 1:5k;
TH 1:15k) and secondary antibody dilutions (Alexa 546 and Alexa 488 1:2k) were optimized for
qualitative comparisons in the caudate putamen. Superfrost slides with mounted sections were
air-dried, covered with glass coverslips using 50% TBS/50% glycerol, sealed with nail polish,
and stored at 4 °C until imaging analysis was performed.
Table 3. Primary Antibodies Used In This Study
Name

Manufacture

Host Species

Lot #

Cat #

Millipore

Rabbit

NG1881779

AB5084P

Millipore

Mouse

NG1802536

MAB318

Santa Cruz

Goat

N/A

Sc-1433

Millipore

Rat

LV1830077

MAB369

Sigma Aldrich

Rabbit

N/A

A 2066

Anti-Dopamine D2
Receptor

Anti-Tyrosine
Hydroxylase, clone
LNC1

DAT (C-20)
(Western)

DAT-Nt
(Immunohisto)

Anti-Actin

Biotechnology, Inc.

(Incubation of all primary antibodies for western blot were at 1:1000 dilutions)
(Dilutions for immunohistochemical analyses were DAT 1:5k and TH 1:15k)
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2.10 Statistical Analysis
Statistical analysis of the resulting data obtained from METH IVSA studies and western
blot analysis were conducted by using SPSS Statistics 17.0.0 (IBM Corporation, Armonk, NY).
The mean METH consumption (mg/kg) in rats given extended or limited access to METH IVSA
during the first hour of self-administration was evaluated via two-sample student t-test between
the groups for all sessions. Total METH consumption (mg) was calculated for each session by
obtaining the product of the number of daily active lever presses and the total amount of METH.
The resulting products were then divided by the subject’s weights for each session in order to
obtain the daily METH consumption in mg/kg.
A one-way repeated measure ANOVA was used to evaluate the mean DAT, D2R and
TH densitometry values obtained from rats that completed the METH IVSA studies. For all
proteins of interest, Actin-normalized arbitrary units of immunoreactivity were obtained from
Adobe Photoshop’s histogram measurement analysis for each condition. These values were
then transformed into the fold change of the adjusted drug naïve condition which was centered
on a value of “1”. This was done to ensure accuracy when depicting the drug naïve condition
(allows for SEM to be shown) and to ensure comparative precision of the arbitrary units of
density between multiple western blots. The results obtained from all one-way ANOVA analyses
were confirmed with Tukey’s HSD post hoc analysis.
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CHAPTER 3: RESULTS
3.1 Methamphetamine Self-Administration in Wistar Rats
IVSA studies are described as a progression in drug consumption entailing a transition
from a low starting intake to progressive and consistently high intake over time (Ahmed&Koob,
1998). Traditional uses of animal IVSA studies are aimed to mimic the behavioral transition from
recreational use to escalated human drug consumption under various classical conditioning
cues. In addition, many pre-clinical studies have demonstrated this transition in various animal
models by displaying a dramatic progressive escalation in drug consumption during IVSA
(Ahmed et al., 2000; and Koob et al., 2006). The rate of METH escalation maybe both dosage
and access dependent as shown by Koob et al., (2006) when comparing 1 hr to 6 hrs daily
access rats at various METH dosage concentrations. However, it remains unclear if progressive
drug escalation can occur at lower concentrations of self-administered METH to those used
elsewhere (Koob et al., 2006).
To answer whether a 0.025 mg/infusion fixed concentration of METH leads to
progressive METH escalation, we set up an operant conditioning study to differentiate the rate
of METH IVSA escalation between rats which were allotted 6 hrs daily METH relative to 1 hr
daily access at the fixed concentration of 0.025mg/infusion, a dosage concentration previously
not well described in literature. The extended access self-administration paradigm experiments
were adapted Koob et al., (2006) and are detailed in Table. 2. The study involves an initial
phase of acquisition, in which all rats received daily 1 hr access to METH for the first six
sessions. The results from Figure 2.1 displays the average mg/kg METH IVSA (mean ± SEM)
for both extended (n=10) and limited access (n=7) conditions during initial six sessions (IVSA
sessions 1-6). Homogeneity of variance was verified prior to every one-way ANOVA conducted
using Levene’s test of homogeneity of variance. A two sample student t-test indicated that no
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significant difference existed between extended and limited access conditions during all
sessions of the METH IVSA acquisition phase. Following the acquisition phase of the study, all
treatment animals were split into 6 hr (extended) and 1 hr (limited) daily METH IVSA access
groups based on total equivalent presses calculated during the acquisition.
Maintaining the fixed dose of 0.025 mg/infusion each treatment groups was allotted 22
days to self-administer METH. The sessions following the acquisition are defined as the
escalation phase of the behavioral conditioning. The escalation phase allotted each METH
treatment group daily access 6 days a week with a break from access on Sundays. Results
depicted in Figure 2.2 displays the average METH IVSA intake (mg/kg) (mean ± SEM) during
the first hour of treatment for all subjects assigned to either extended (ExA) or limited access
(ShA) during both acquisition phase (IVSA sessions 1-6) and escalation phase (IVSA sessions
7-28). A two sample student t-test revealed a significant difference during the first hour of METH
IVSA intake between extended and limited access rats (Table 4). As shown in the Figure 2.2
animals with ExA displayed a progressive transition from a controlled form of administration to
an arguably uncontrolled form of METH intake, characterized by a significant escalation in drug
consumption relative to ShA (Figure 2.2). A significantly greater amount of METH was
consumed (mg/kg) by subjects assigned to the ExA condition relative to subjects within the ShA
on specific sessions during the escalation phase (Table 4). A summary of the average daily
METH consumption (mg/kg) during the first hour and entire METH IVSA session for both
treatment conditions is shown in Figure 2.3. As expected, ExA rats had a significantly larger
total METH consumption (mg/kg) daily during the escalation phase when compared to ShA
(Figure 2.3). These results altogether demonstrate that rats given ExA displayed a significant
escalation in METH consumption (mg/kg) (mean ± SEM) during the first 60 mins of IVSA
relative to ShA, and finally a larger METH intake compared to ShA animals.

22

3.2 METH-induced changes in select dopaminergic proteins
Several studies have described persistent dopaminergic alterations following access to
METH in both human and rodent animal models (Wilson et al., 1996, Volkow et al., 2001,
Krasnova et al., 2010 and McFadden et al., 2012). In rat, DAT and TH were both shown to be
down regulated at 7, 9, 14 and 30 days following the final METH IVSA session in large dosage
(0.06 mg/infusion fixed for 500 g; 0.1+ mg/kg/infusion) regimens (Krasnova et al., 2010;
McFadden et al., 2012 and Hanson et al., 2009). However, D2 receptor levels in the striatum
have not been shown to change in rats that had actively self-administered METH at
0.1mg/kg/injection at 7 and 30 days following METH abstinence when compared to yoked
controls (Stefanski et al., 2002). While down regulation of DAT and TH during prolonged periods
of abstinence after brief large dose METH IVSA regimens is well characterized, the expression
of these proteins 24-72 hrs following an extended METH IVSA paradigm using 0.025
mg/infusion fixed for 500 g is not well established.
To address this gap in the literature, total DAT, TH and D2R protein levels were
measured via western blot analysis from homogenized striatal lysates of all animal subjects
after 72 hrs following the final METH IVSA session. Following conscious rapid decapitation, the
striatum was extracted and the contents of the tissue consisted mainly of caudate putamen
(CPu) and nucleus accumbens (NAc) from both hemispheres. The striatal tissue was
homogenized with a lysis buffer followed by centrifugation and protein quantification. A total of
30 µg protein from each lysate was subjected to SDS-PAGE and western blotting.
Immunoreactivity of total striatal D2R, DAT, TH, and β-Actin expression (52-kDa, 72-kDa, 56kDa, and 42-kDa respectively) were measured from subjects in either extended, limited, or
naïve conditions. The total amount of DAT, TH and D2 relative to the β-Actin loading control
was calculated for each sample by densitometry. As shown in Figure 3.1, western blot analysis
revealed a 1 fold increase on total striatal DAT expression among ExA rats relative to ShA and
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naïve controls. The average of three repeated measures for each target marker was normalized
to the mean of control and statistically evaluated via one-way repeated measure (RM) ANOVA
analysis. The mean densitometry values are presented in Figures 3.1-3.3 for each condition as
the fold change of the naïve condition ± SEM.
Statistical analysis revealed that ExA METH intake had a significant increase on
measured DAT expression in the striatum relative to naïve control (Figure 3.1), F (2, 9) = 8.57, p
< .01, η2 = .61. In addition, post hoc comparisons using Tukey’s HSD test (p < .01 ) suggests a
significant increase in measured DAT immunoreactivity in subjects receiving ExA to METH IVSA
relative to naïve control, t(18) = 3.48, p < .01 (2-tailed), η2 = 0.72. By contrast, one-way RM
ANOVA revealed that METH intake did not have a significant effect on TH expression (Figure
3.2), F (2, 9) =2.661, ns and D2R expression (Figure 3.3), F (2, 9) =0.941, ns within the
striatum between treatments ShA and ExA as compared to naïve control 72 hrs following the
final METH IVSA session. Taken together, these results demonstrate a significant up regulation
in striatal DAT expression among ExA as compared to naïve controls.
DAT and TH expression was also surveyed using immunohistochemical labeling
methods with 30µm thick coronal sections featuring the caudate putamen of the striatum.
Preliminary results for DAT and TH labeling appear to follow a similar pattern of expression
compared to the western blot analyses (Figure 3.4-3.5). However, there are some regional
differences in DAT and TH expression through the striatum that remains to be further
investigated (Figure 3.6-3.7).
We conducted a bolus METH (4 x 5 mg/kg) administration study and acquired
preliminary data for DAT expression after 3, 4, and 5 days following administration. In this study,
rats received 5 mg/kg subcutaneous injections (s.c.) of either saline or METH every 4 hrs for a
total of 20 mg/kg. Striatal tissue was harvested 3, 4, and 5 days following the bolus
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administration and lysates were subjected to SDS-PAGE and western blotting with DAT
antibody. Preliminary data (N=1) revealed that striatal DAT expression 3 days following bolus
administration did not follow striatal DAT expression found 3 days following our extended
access METH IVSA study (Figure 3.8). Furthermore, we found that striatal DAT expression may
fluctuate 4 and 5 days follow bolus administration (Figure 3.8-3.9). The differences in total
striatal DAT expression 3 days following our extended access METH IVSA study relative to our
bolus administration study requires further investigation.
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Acquisition phase of METH intake for ShA and ExA conditions

Figure 2.1 – Acquisition phase of METH intake (mg METH/kg; mean ± SEM) for both
extended and limited access conditions. Wistar rats were allowed to self-administer METH for
1 h daily. The total METH (mg)/kg is plotted per session No significant differences in METH IVSA
were observed between conditions during any session of the acquisition phase (p>.05, condition
1h versus 6h)

First Hour of METH intake between ShA and ExA

Figure 2.2 - First hour of METH intake (mg/kg) during acquisition and escalation phases in
rats given extended (n=10) or limited (n=7) access. Daily values are averaged within each
group (group mean±SEM). Statistical analysis indicated a significant difference in METH IVSA
during the first hour of treatment between conditions on sessions marked * (p < .05).
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Table 4. - Sessions of METH intake between ExA and ShA that
displayed statistical significance
Session#11

Session#18

Session#20

Session#22

Session#23

Session#24

Session#28

t(17)= 2.41
t(17)= 2.16
t(17)= 2.27
t(17)= 2.72
t(17)=3.03
t(17)= 2.18
t(17)= 2.74
p < .05 (2- p < .05 (2- p < .05 (2- p < .05 (2- p < .01 (2- p < .05 (2- p < .05 (2tailed)
tailed)
tailed)
tailed)
tailed)
tailed)
tailed),
η2 = .28

η2 = .24

η2 = .26

η2 = .33

η2 = .38

η2 = .24

η2 = .33

Legend: t=”test statistic” p=”probability” η=” between subject number”

Total Meth intake between ShA and ExA conditions

Figure 2.3 - Total average daily METH consumption (mg/kg+SEM) during the entire METH
IVSA study. Graph displays METH intake as a function of session (day) for extended (ExA,
n=10) and limited access (ShA, n=7). Solid gray dots represent the daily total METH
consumption (mg/kg+SEM) for the full ExA session duration. Solid black dots represent daily
METH consumption (mg/kg+SEM) during the first hour of each ExA session. White dots
represent the daily total METH consumption (mg/kg+SEM) for the full 1 hour ShA session
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Total DAT Expression in the Striatum

Figure 3.1- DAT levels in striatum from naïve and METH treated rats. Wistar rats were
treated with saline (naïve) or METH as described under experimental procedures. After
treatment, tissue lysates from striatum were subjected to electrophoresis and western blotting
with DAT antibody. ANOVA indicated that a significant increase (p<.01) in measured dopamine
transporter immunoreactivity was observed in rats receiving extended METH IVSA versus naïve
control, indicated on the graph by (*).The bottom panel depicts the results of the densitometry
analysis for striatal DAT immunoreactivity with the 72-kDa and 42 –kDa range bands for DAT
and Actin respectively.
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Total TH Expression in the Striatum

Figure 3.2- TH levels in striatum from naïve and METH treated rats. Wistar rats were
treated as described in Figure 3.1 and striatal lysate subjected to blotting with Tyrosine
hydroxylase antibody. ANOVA indicated no significant difference in measured total striatal TH
between all conditions (p>.05). The bottom panel depicts the results of the densitometry
analysis for striatal TH immunoreactivity with 56-kDa and 42 –kDa range bands for TH and
Actin respectively.
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Total D2R Expression in the Striatum

Figure 3.3- Dopamine receptor levels in striatum from naïve and METH treated rats. Wistar
rats were treated as described in Figure 3.1 and striatal lysate subjected to blotting with Dopamine
Receptor 2 antibody (D2R). ANOVA indicated no significant differences in measured total striatal
D2R between all conditions (p>.05). The bottom panel depicts the results of the densitometry
analysis for striatal D2R immunoreactivity with 52-kDa and 42 –kDa range bands for D2R and
Actin respectively.
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DAT Expression in the Caudate Putamen (Level 24)

Figure 3.4- Comparison of DAT expression in naïve and METH treated rats. All rats were
perfused and the collected brain tissue was sectioned at 30µm thickness. Sections were
stained using primary DAT and secondary Cy3 antibodies. All stained sections were mounted
and imaged using an inverted fluorescence microscopy at 10X focusing on top left hemisphere
of the caudate putamen at section level 24 according to Paxino’s atlas.

TH Expression in the Caudate Putamen (Level 24)

Figure 3.5- Comparison of TH expression in naïve and METH treated rats. All rats were
perfused and the collected brain tissue was sectioned at 30µm thickness. Sections were
stained using primary TH and secondary Alexa 488 antibodies. All stained sections were
mounted and imaged using an inverted fluorescence microscopy at 10X focusing on top left
hemisphere of the caudate putamen at section level 24 according to Paxino’s atlas.
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DAT Expression in the Caudate Putamen (Level 35)

Figure 3.6- Comparison of DAT expression in naïve and METH treated rats. All rats were
perfused and the collected brain tissue was sectioned at 30µm thickness. Sections were
stained using primary DAT and secondary Cy3 antibodies. All stained sections were mounted
and imaged using an inverted fluorescence microscopy at 10X focusing on top left hemisphere
of the caudate putamen at section level 35 according to Paxino’s atlas.

TH Expression in the Caudate Putamen (Level 35)

Figure 3.7- Comparison of TH expression in naïve and METH treated rats. All rats were
perfused and the collected brain tissue was sectioned at 30µm thickness. Sections were
stained using primary TH and secondary Alexa 488 antibodies. All stained sections were
mounted and imaged using an inverted fluorescence microscopy at 10X focusing on top left
hemisphere of the caudate putamen at section level 35 according to Paxino’s atlas.
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Percentage of density

Striatal DAT Expression: Days 3 and 4 following bolus administration

Day 3 Following Bolus Administration
1.500
1.000
0.500
0.000

1.000
0.655

0.692

0.360

0.254

0.225

0.219

0.191
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Saline Ctrl Saline Ctrl Saline Ctrl Saline Ctrl Meth 39 Meth 38 Meth 34 Meth 25
31
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33
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Percentage of density

Day 4 Following Bolus Administration
1.500

1.000

1.000
0.500

0.189

0.492

0.348

0.668
DAT

0.000
Saline Ctrl 29

Saline Ctrl 24

Saline Ctrl 28

Meth 27

Meth 41

DAT normalized values

Figure 3.8- DAT expression in METH rats relative to the saline control conditions 3 and 4
days following bolus administration. Rats received either 5 mg/kg METH or saline solution
every 4 hours for 16 hours total via subcutaneous injections resulting in a total of 20 mg/kg
administered. Control and METH treated rats were sacrificed 3 and 4 days following bolus
administration (20 mg/kg) and striatal tissue was extracted and subjected to western blotting
using DAT antibody as described in Figure 3.1. The bottom panel depicts the results of the
densitometry analysis for striatal DAT immunoreactivity with the 72-kDa and 42 –kDa range
bands for DAT and Actin respectively. (N=1)
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Striatal DAT Expression: Day 5 following bolus administration

Day 5 Following Bolus Administration

Percentage of density
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DAT normalized values

Meth 40
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Figure 3.9- DAT expression in METH rats relative to the saline control conditions 5 days
following bolus administration. Rats received either 5 mg/kg METH or saline solution every 4
hours for 16 hours total via subcutaneous injections resulting in a total of 20 mg/kg
administered. Control and METH treated rats were sacrificed 5 days following bolus
administration (20 mg/kg) and striatal tissue was extracted and subjected to western blotting
using DAT antibody as described in Figure 3.1. The bottom panel depicts the results of the
densitometry analysis for striatal DAT immunoreactivity with the 72-kDa and 42 –kDa range
bands for DAT and Actin respectively. (N=1)
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS
4.1 DISCUSSION
Extended (6hr) and limited (1hr) access groups self-administered METH for 22 days
following the acquisition phase. Daily total presses for METH were recorded for all treatment
animals and normalized by body mass to calculate total mg/kg. We predicted that extended
access rats would demonstrate an escalation of METH intake during the initial hour of access
compared to limited access rats, similar to the results obtained by Koob et al., (2006).Consistent
with this idea, we detected a significant increase (p<.05) in METH consumption (mg/kg)
(escalation) during the first hour of administration in rats given extended access to METH IVSA
relative to limited access on seven separate IVSA sessions. The escalation effect in extended
access relative to limited occurred mainly during the final 10 days of METH IVSA. Among
extended access, there were episodes of binge-like intake during METH IVSA. Binges of METH
intake did not fall on sessions following the Sunday break from access. The average daily
METH intake for limited access was approximately 1.25 mg/kg, while the extended access
average daily METH intake was about 5.5 mg/kg. Thus, the total average daily METH intake
among extended access rats was about 5 times the total METH intake compared to limited
access rats.
Seventy-two hours after the final METH IVSA session striatal tissues from all rats were
extracted for protein expression measurement via western blot. The analysis revealed a
significant increase (p<.01) in total striatal DAT among extended access rats relative to naïve
control. No significant difference was found in total striatal TH expression in rats given access to
METH IVSA relative to naïve controls. In addition, no significant difference was found in total
striatal D2R expression levels between any conditions.
Rats were also perfused 72 hrs following the final METH IVSA session and (30 µm)
coronal sections of the midbrain were collected in 5 series. Preliminary immunohistochemical
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results revealed a pattern of protein expression for DAT and TH similar to that found in the
striatal western blot analysis in specific coronal sections featuring the caudate putamen.
However, we also observed regional differences in expression for DAT and TH in various
sections of the caudate putamen surveyed. The differences in DAT and TH expression
throughout the caudate putamen and other anatomically important dopaminergic areas will
require further investigation.
The effects of METH injection on dopaminergic systems has also been studied in rats
and mice, the results derived from these studies suggest that days after a bolus injection of
METH there is a gradual loss of DAT, TH and D2R over time in the striatum (Zhu, Xu & Angulo,
2005). With this in mind, a bolus METH administration (4 x 5 mg/kg) study was conducted in
which rats would receive either METH or saline injected subcutaneously. Preliminary results
revealed that striatal DAT expression was lower in METH treatment rats compared to saline
controls 3 and 5 days following bolus administration. In contrast, results obtained 4 days
following bolus administration revealed an increase for striatal DAT expression among METH
treated rats compared to saline controls. The observed fluctuation in DAT expression 3, 4 and 5
days following bolus METH administration may reflect a multi-phasic compensatory response
resulting from neurotoxicity following large doses of administered METH. However, further
investigation is required to determine neurotoxicity and/or mutli-phasic compensatory responses
following our bolus administration paradigm.
Results from our METH IVSA study paralleled the findings found in other similar
extended access studies. An extended access METH self-administration paradigm conducted
by Koob et al., (2006) over a period of 21 days revealed a significant escalation of drug intake
among rats given 6 hrs daily access compared to rats given 1 hr daily access. When the METH
concentration was increased from 0.033mg/kg/infusion to 0.1mg/kg/infusion the rate of
escalation increased significantly (Koob et al., 2006). In cases of extended access to cocaine,
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rats exposed to 6 hrs of daily access for 21 days displayed a gradual escalation over both first
hour and total drug intake when compared to rats exposed to 1 hr per day, where drug intake
remained low and stable (Ahmed and Koob 1998). A similar escalation of acquisition emerged
in heroin self-administration following 11 h daily access (Ahmed et al., 2000). Based on the
aforementioned experiments, the rate of drug escalation is both dose and access dependent.
Our IVSA results demonstrate that extended access (6 hrs) to METH at the low fixed dosage of
0.025mg/infusion produces a progressive increase of drug intake possibly indicative of a
transition leading to addiction when compared to limited access (1 hr). However, Koob et al.,
(2006) and other similar extended access studies (Ahmed et al., 2000; Ahmed and Koob 1998)
did not follow up on the potential dopaminergic changes associated with this transition following
their extended access self-administration paradigm.
While the majority of animal METH studies report significant decreases in dopaminergic
protein expression following METH abstinence, Keller et al., (2011) reports results which parallel
our own. When METH is administered for 14 days in an escalating-dose paradigm mimicking
self-administration, results demonstrate a biphasic response of DA regulation in the
mesoaccumbens pathway based on acute versus prolonged tissue harvest time points (Keller et
al., 2011). For example, western blot analysis revealed that 48 hrs after METH treatment a
significant increase of DA, DAT and TH was found in the ventral tegmental area (VTA) and a
decrease of DA, DAT and TH was found 14 days later in the VTA as compared to naïve controls
(Keller et al., 2011).
The METH administration paradigm employed by Keller et al., (2011) may not be
considered extended access since the duration did not exceed a total 20 days of administration.
However, these results are of particular interest in demonstrating how an escalation-dose
paradigm of longer duration could both transiently and persistently alter DA functioning in the
reward pathway during various periods of withdrawal. This contradicts the notion that DAT
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levels persistently decline following consumption and immediate cessation of METH, and
supports our body of work. However, it is important to note that METH administration, dosage
and duration vary between our study and that of Keller et al., (2011).
In all, our study observed two significant effects among rats granted extended access (6
hrs) to METH. The first effect revealed that rats given 6 hrs daily access to METH had a
significant accelerated rate of intake (mg/kg) during the initial hour of self-administration relative
to rats given 1hr access. The second effect revealed a significant increase in total striatal DAT
among rats given 6 hrs daily access to METH compared to naïve controls. We believe both
effects are connected in a causal relationship (Figure 4.1). The significant escalation of total
METH intake facilitates an enhancement of extracellular DA during self-administration. The
enhancement of extracellular DA release induces a compensatory response resulting in a
significant increase of DAT. In attempt to maintain homeostatic DA signaling the increase of
DAT aids in the clearance of the METH induced DA releases. We believe the up regulation of
DAT, in response to enhanced METH induced DA release, may be involved in facilitating both
binge like episodes and continued escalation of drug intake.
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Cyclical relationship between METH intake and DAT up regulation

Figure 4.1 – Cyclical relationship between METH intake and DAT up regulation. (1.)
ExA METH IVSA intake results in enhancement of extracellular DA in the striatum. (2.)
Enhancement of extracellular DA results in an increase of DAT in the striatum. (3.) Up
regulation of DAT leads to enhanced uptake of extracellular DA in the striatum. (4.)
Enhanced re uptake of DA results in extracellular DA depletion and reduced DA signaling.
Reduction of DA signaling away from METH leads to increased METH intake and binge
episodes when granted access to METH IVSA.

Our original hypothesis predicted an overall down regulation of dopaminergic proteins
within the striatum of the METH treatment animals in an access dependent manner. The
rationale for our hypothesis was based on a number of rodent METH IVSA reports finding
significant down regulation of dopaminergic proteins (DAT, TH, D1R and D2R) in various
regions of the striatum following periods of prolonged METH abstinence (Cadet et al., 2003;
Hanson et al., 2004; Krasnova et al., 2010; McFadden et. al., 2011; Schwendt et al., 2009; Volz
et al., 2007). In addition, clinical studies in human addicts have reported a 30-60% decrease in
DA and DAT in the striatum or NAc (Wilson et al., 1996; McCann et al., 1998 & 2008; and
Volkow et al., 2001). A 20% decrease of the rate-limiting DA synthesis enzyme TH was found
among human addicts within the striatum (Wilson et al., 1996). The deficits found in
dopaminergic systems may be persistent several years after METH abstinence in some users.
For example, that underwent abstinence for a period of 3 years showed significant decreases in
DAT density in the caudate nucleus and putamen as assessed by PET scans (McCann et. al.,
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1998). These various clinical findings have informed pre-clinical experimental design and
identified proteins of interest for measurement after periods of METH intake.
Indeed, several pre-clinical rodent IVSA studies have also demonstrated that repeated
exposure to METH results in persistent dopaminergic deficits for DA and DAT, but with some
variability (Volz et al., 2007; Hanson et al., 2009; Krasnova et al., 2010; and McFadden et al.,
2012). Animals assessed 8 or 30 days after the last METH IVSA session (0.06 mg/infusion; 8hr
sessions for 7 days) revealed a decrease in both striatal DAT expression and DA uptake
(McFadden et. al., 2011). Striatal dopaminergic protein deficits were found in other reports with
similar METH IVSA paradigms and parameters (Volz et al., 2007 and Hanson et al., 2009).
However, considering that METH dose, exposure history, dosing interval, IVSA access
durations and tissue harvest times are critical factors in characterizing METH’s effect on DA
signaling, any alteration in these parameters can lead to significant deviations. For example,
when less METH is available (0.02 mg/kg/injection for up to 6 to 7 mg/kg daily intake), as shown
by Schwendt et al., (2009), there are no significant effects on DA tissue content in the NAc, and
little, if any, effect on TH 2-weeks following METH IVSA. However, allowing rats to selfadminister much higher concentrations of METH for longer durations (0.1 mg/kg/injection for
15hrs a day for 8 days, up to 14 mg/kg daily) will significantly decrease striatal DA content, TH,
and DAT within 24 hrs and the effect remains for at least 2 weeks (Krasnova et al., 2010).
High-dose METH IVSA regimens are associated with METH induced DA neurotoxicity
(Thomas et al., 2009). The association is attributed to overall down regulation of dopaminergic
marker proteins such as DAT, TH and synaptic DA receptors. METH-induced oxidative stress
within the neuron is one factor proposed to contribute to cellular dysfunction through disruption
of the mitochondrial election transport chain (Wu et al., 2007). In human addicts, it is speculated
that chronic METH use can produce persistent deficits in DA reuptake through reductions in
DAT and/or impair DA synthesis through TH loss via dopaminergic neuronal death (Wilson et
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al., 1996). However, the measurement of such dopaminergic markers is widely considered an
indirect measurement of neurotoxicity, and direct evidence of neuronal death has not been well
established. Yet, METH induced neurotoxicity to DA neurons as a consequence of chronic
METH use has taken center stage as the speculated contributing factor in evoked DA reduction
and dopaminergic dysfunction.
Taken together, these studies conclude that after prolonged periods of METH
abstinence, persistent dopaminergic deficits may remain in chronic users. In addition, some
studies posit persistent deficits may be directly associated with the death of DA neurons within
the striatum. However, studies in which investigators have examined the persistent
dopaminergic effects of METH self-administration in rodents have not done so following an
extended access METH IVSA paradigm. Furthermore, many of these studies did not exceed
more than 7 to 9 days of drug access (Krasnova et al., 2010, Hanson et al., 2009, McFadden et
al., 2012, and Cadet et al., 2003). Studies that have found persistent dopaminergic deficits have
done so using high concentrations of self-administrated METH (0.06 mg/infusion or higher) for
long daily durations (8hrs or more). Moreover, tissue harvest time points vary among models
from 7 to 30 days after final METH self-administration, neglecting the potential of significant
changes from zero to 6 days following extended access regimens.
In experiments where either daily METH access or METH concentration (mg/kg/infusion)
have been reduced, no significant dopaminergic changes are established following prolonged
periods of METH abstinence. Two independent groups of investigators conducting METH selfadministration in rat models using relatively small doses with either 2 hrs or 9hrs/daily access
failed to find any evidence of significant neurotoxic damages in dopaminergic terminals
(Stefanski et al., 2002 and Shepard et al., 2006 respectively).
Variability in dosage, consumption and access as it relates to dopaminergic changes in
the brain may also been seen among human METH users. Indeed, DAT can recover to near-
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baseline levels in human subjects who have managed to remain abstinent from previous METH
use (Volkow et al., 2001). However, it remains unclear what factors govern DA and DAT
recovery in abstaining METH users. Findings such as these are beginning to outline a
mechanistic model by which the persistent loss of DAT or any other dopaminergic proteins may
not necessarily be indicative of METH-induced neurotoxicity in terms of cell death, but rather a
departure from normal cellular function.
4.2 SPECULATION AND CLINCAL IMPLICATIONS
Our results demonstrated the effect of extended access METH intake on dopaminergic
markers in the striatum during the 72-hr period of acute withdrawal. The effect on ExA DAT
levels in the striatum may result from a gradual increase of METH intake among ExA rats
relative to ShA during the first 60 min or differences in total mg/kg. Escalation in METH
consumption may be required to increase DAT expression within the striatum. The changes in
ExA DAT expression may be related to compensatory mechanisms evoked by progressively
elevated synaptic DA levels during drug conditioning. Our results are in conjunction with the
findings applying METH IVSA paradigms revealing non-significant TH depletion (Schwendt et
al., 2009; Stefanski et al., 2002; Shepard et al., 2006) suggest that low-dose IVSA procedures
may be used to study neuroplasticity accompanying METH intake. Thus, METH mediated
attenuation of DAT, TH and synaptic DA receptor levels may arguably be the functional result of
compensatory mechanisms accompanying METH exposure. The results taken together may
reveal a compensatory mechanism involving changes in protein expression following the
absence of direct DAT functional modification by METH in specific regions of the striatum.
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Compensatory Model of METH Induced DA Depletion

Figure 4.2 – ExA METH IVSA results in dopaminergic protein changes in the striatum
compared to naïve control. Arrows in black indicate significant differences, and arrows in
white indicate either predicted changes (↓) or trending changes with no significance. Symbol –
indicates no significant differences. Changes among DAT and TH may result in lower DA
synaptic availability during acute periods of METH withdrawal.

The associated behavioral effects of the proposed compensatory model (Figure 4.2)
during periods of acute METH abstinence have not been well characterized. However, clinical
case studies have revealed that drug craving and relapse along occurs mainly during periods of
acute withdrawal (Newton et al., 2004; McGregor et al., 2004). Within our study, increases in
striatal DAT in conjunction with a possible minor attenuation of striatal TH expression will
certainly impede dopaminergic neurotransmission via lower synaptic DA levels. Synthesis of DA
may suffer a minor deficit in response to TH expression impeding the rate in catalyzing tyrosine
to L-3, 4-dihydroxyphenylalanine (L-DOPA). Through the combination of a robust increase in
DAT and minor decrease in TH, DA receptor activation would become severely hindered
through the agency of enhanced synaptic DA uptake from marginal pre-synaptic DA output.
Although further study of synaptic DA availability during this period of abstinence is required, it
is logical to suggest that the potential deficit of DA neurotransmission may attribute to the
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severity of withdrawal symptoms and/or drug craving experienced by human METH addicts
during the initial 72-hr period of abstinence.
While the employed extended access METH IVSA paradigm in this study may not fully
mimic illicit METH consumption within human populations, the escalation in consumption
relative to access does translate clinically. Escalation in drug consumption overtime particularly
translates well among AMPH and METH based prescription drug users. Some users of
prescribed METH and AMPH based drugs may find themselves physically dependent after
several weeks of gradual escalation in attempt to achieve their desired therapeutic effect. When
these users run out of medication some may attempt to acquire the drug through illegal avenues
in attempt to avoid the symptoms that occur during acute withdrawal. The findings of the current
study model the role of three essential dopaminergic regulatory proteins within the striatum
during this critical period of METH abstinence. The changes in DAT expression may inform
clinical treatments, as our results imply that a deficit of dopaminergic transmission may exist
during 72-hr periods of abstinence, which may attribute to the severity of withdrawal symptoms
and/or drug craving experienced by METH addicts.
In the context of the present results, administration of a DAT inhibitor may reduce the
probability of relapse by attenuating the severity of withdrawal symptoms experienced during
the initial hours of METH abstinence by increasing synaptic DA levels and improving DA
neurotransmission. Investigations of opposing psycho stimulant effects on DAT availability have
provided therapeutic evidence for the use of AMPH in the treatment of cocaine dependence,
which is currently in early clinical trials (Grabowski et al., 2001: see Castells et al., 2007 for a
review). However, the therapeutic relevance of DAT inhibition for the treatment of AMPH or
METH dependence remains unclear due to a lack of investigation. Consequently, the
development of atypical DAT inhibitors with low abuse potential currently remains to be
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explored, thus leaving Modafinil or possibly methylphenidate (Ritalin) as the pharmacological
agent of choice in the context of this study when treating METH withdrawal.
4.3 FUTURE DIRECTIONS
Our study has conducted preliminary immunohistochemical staining with antibodies
against DAT and TH. This approach allows for the specific identification of proteins
corresponding to anatomical locations, such as the ventral and dorsal striatum among METH
rats as compared to naive controls. Throughout the majority of the CPu, preliminary data
analysis for DAT and TH immunohistochemical expression appears to follow a similar pattern as
revealed in the quantitative striatal lysate western-blot results. However, histological staining of
DAT and TH is currently interpreted on a qualitative basis and regional differences were also
observed. A more quantitative approach to DAT and TH expression measurement within various
anatomical areas of the striatum should be attempted.
Daily access to METH exposure does not fully mimic a model of illicit human
consumption. During certain periods within the extended access paradigm there were episodes
of binge-like METH intake. To better model illicit human consumption of METH we should
employ a revised extended access paradigm in which animals are forced to abstain for up to
72hrs following binge-like episodes. This revised design may allow us to more accurately model
how METH is consumed within the human population and learn how periods of acute withdrawal
may possibly contribute to heightened drug reinstatement.
Measurement of Synaptic DA depletion in the striatum of rats experiencing acute METH
withdrawal should be conducted with chronoamperometry procedures. Chronoamperometry is a
technique which allows for the In vivo measurement of extracellular neurotransmitters with
temporal resolution in milliseconds. This will allow us to better understanding the physiological
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changes of DA release and DAT function at the synapse during periods of acute withdrawal
following extended access METH IVSA exposure.
Lastly, to address possible compensatory mechanisms during the acute periods of
withdrawal, we require time courses for western blot analysis of total striatal tissue concomitant
with isolations of better defined NAc and CPu regions. Alternative time points for tissue
collection following METH IVSA will allow us to assess any additional changes in protein
expression that may be compensatory or have biphasic relationships relative to expression at
earlier time points.
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